TheranosticTrials.org

Clinical Trial · NCT02440308

68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer

Overview

This clinical trial studies the use of gallium-68 (68Ga)-DOTA-Bombesin as the imaging agent for positron emission tomography (PET)/magnetic resonance imaging (MRI), collectively PET-MRI, in patients with prostate cancer. PET uses a radioactive substance called 68Ga-DOTA-Bombesin, which attaches to tumor cells with specific receptors on their surfaces. The PET scanner takes pictures that capture where the radioactive drug is "lighting up" and attaching to tumor cells, which may help doctors recognize differences between tumor and healthy prostate tissue. MRI uses radio waves and a magnet to make a picture of areas inside the body. Using 68Ga-DOTA-Bombesin in diagnostic procedures, such as PET/MRI, may allow doctors to identify smaller tumors than standard imaging.

Sponsor

Stanford University

Phase

Phase 2

Contacts

Andrei Iagaru (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02440308

Drug / Compound

Bombesin

Isotope(s):
Target(s):
  • GRPR
Ligand Class: Peptides
Chelator: DOTA

Eligibility

Inclusion

  • Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance
  • Metallic implants
  • INCLUSION CRITERIA
  • Patient has suspected recurrence based on biochemical data \[prostate-specific antigen (PSA) \> 2 ng/mL\]
  • Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
  • Able to remain still for duration of each imaging procedure (about one hour)EXCLUSION CRITERIA
  • Inability to lie still for the entire imaging time
  • Known diagnosis of prostate cancer

Exclusion

Exclusion criteria not yet provided.